Analysts Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Earnings of -$0.30 Per Share
Wall Street analysts forecast that CymaBay Therapeutics Inc (NASDAQ:CBAY) will announce earnings of ($0.30) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for CymaBay Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.23). CymaBay Therapeutics reported earnings of ($0.21) per share in the same quarter last year, which would suggest a negative year over year growth rate of 42.9%. The business is expected to issue its next earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that CymaBay Therapeutics will report full-year earnings of ($1.19) per share for the current year, with EPS estimates ranging from ($1.26) to ($1.01). For the next financial year, analysts anticipate that the firm will post earnings of ($1.18) per share, with EPS estimates ranging from ($1.46) to ($0.46). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow CymaBay Therapeutics.
CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.04).
Shares of NASDAQ:CBAY traded down $0.68 during trading on Tuesday, reaching $11.39. The company had a trading volume of 1,297,666 shares, compared to its average volume of 390,113. The firm has a market capitalization of $672.61 million, a price-to-earnings ratio of -14.42 and a beta of 1.98. CymaBay Therapeutics has a 12 month low of $7.36 and a 12 month high of $15.59.
In related news, VP Daniel Menold sold 5,000 shares of the stock in a transaction on Wednesday, August 29th. The shares were sold at an average price of $13.00, for a total transaction of $65,000.00. Following the transaction, the vice president now owns 5,000 shares of the company’s stock, valued at approximately $65,000. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.50% of the stock is currently owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in CBAY. Hillsdale Investment Management Inc. bought a new position in shares of CymaBay Therapeutics during the 1st quarter valued at $104,000. LPL Financial LLC purchased a new stake in CymaBay Therapeutics during the 1st quarter valued at $130,000. Legal & General Group Plc purchased a new stake in CymaBay Therapeutics during the 2nd quarter valued at $134,000. State Board of Administration of Florida Retirement System purchased a new stake in CymaBay Therapeutics during the 2nd quarter valued at $145,000. Finally, Teacher Retirement System of Texas purchased a new stake in CymaBay Therapeutics during the 2nd quarter valued at $151,000. 95.44% of the stock is currently owned by institutional investors.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Recommended Story: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.